peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Our commitment to patients at the ESOT 2021 congress

From August 29 to September 1 2021, Hansa Biopharma took part in the European Society for Organ Transplantation (ESOT) Congress.

The biennial ESOT Congress, which typically brings approximately 3,500 medical experts together in pursuit of improved outcomes within transplantation, is among the most important international congresses in the field.

For Hansa, ESOT is a key event that provides the opportunity to share our experience, learn from experts in the transplant community, and connect with stakeholders on how we can continue to work collaboratively on addressing the need of patients with rare immunologic conditions.

At the ESOT congress 2021, Hansa hosted an expert symposium titled focused on highly sensitized patients and their journey to transplantation. The symposium was chaired by Prof. Lucrezia Furian from the University Hospital Padova, Italy. Several experts discussed key approaches to enabling kidney transplants for those patients who are least likely to get access to a compatible transplant. Prof. Furian was joined by several eminent colleagues in transplant medicine, Prof. Stanley Jordan M.D. Ph.D from Cedars Sinai Hospital, Los Angeles; Prof. Nizam Mamode M.D. from Guys Hospital, London; Prof. Denis Glotz from Hospital St Louis, Paris; and Dr. Oriol Bestard from University Hospital Vall d’Hebron, Barcelona.

Hansa is also actively supporting ESOT on key activities and projects focused on advancing medical knowledge on highly sensitized patients. Among many activities, Hansa is partnering with ESOT to sponsor the ESOT Transplantation Learning Journey (TLJ) 2.0 workstream on HLA desensitization. This workstream is composed of a panel of EU thought-leaders chosen by ESOT, whose objective is to generate a consensus on management of highly sensitized patients.

There is a lack of shared consensus when it comes to the management of patients with human leukocyte antigen (HLA) antibodies. Following the work of this workstream, ESOT is now finalizing a consensus on desensitization practice targeted towards transplantation specialists across Europe.